A role for CCL2 in both tumor progression and immunosurveillance

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Li, Ming ^a,b   Knight, Deborah A ^a,b   Snyder, Linda A ^c   Smyth, Mark J ^a,b   Stewart, Trina J ^d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

Breast cancer; CCL2; CCR2; Chemokine; Immunosurveillance; Metastases monoclonal antibody therapy; Tumor progression

Indexed keywords

3 METHYLCHOLANTHRENE; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER MODEL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; GROWTH RATE; IMMUNOSURVEILLANCE; KNOCKOUT MOUSE; LUNG METASTASIS; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIMARY TUMOR; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR GROWTH;

EID: 84886944292     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25474     Document Type: Article

References (27)

1. Stewart TJ, Smyth MJ. Chemokine-chemokine receptors in cancer immunotherapy. Immunotherapy 2009; 1:109-27; PMID:20635978; http://dx.doi. org/10.2217/1750743X.1.1.109
2. Xia Y, Frangogiannis NG.MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy.Inflamm Allergy Drug Targets 2007; 6:101-7; PMID:17692033; http://dx.doi.org/10.2174/187152807780832265
3. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, et al.Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.Clin Cancer Res 2000; 6:3282-9; PMID:10955814
4. Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, Ulbrich E, et al.Monocyte chemoattractant protein-1 serum levels in patients with breast cancer.Tumour Biol 2004; 25:14-7; PMID:15192307; http://dx.doi.org/10.1159/000077718
5. Youngs SJ, Ali SA, Taub DD, Rees RC.Chemokines induce migrational responses in human breast carcinoma cell lines.Int J Cancer 1997; 71:257-66; PMID:9139852; http://dx.doi.org/10.1002/ (SICI)1097-0215(19970410)71:2257::AIDIJC22 3.0.CO;2-D
6. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al.CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.Nature 2011; 475:222-5; PMID:21654748; http://dx.doi.org/10.1038/nature10138
7. Steiner JL, Murphy EA.Importance of chemokine (CC-motif) ligand 2 in breast cancer.Int J Biol Markers 2012; 27:e179-85; PMID:22865298; http://dx.doi.org/10.5301/JBM.2012.9345
8. Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, et al.CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.Cancer Lett 2007; 252:86-92; PMID:17257744; http://dx.doi.org/10.1016/j.canlet.2006.12.012
9. Conti I, Rollins BJ.CCL2 (monocyte chemoattractant protein-1) and cancer.Semin Cancer Biol 2004; 14:149-54; PMID:15246049; http://dx.doi.org/10.1016/j.semcancer.2003.10.009
10. Lança T, Costa MF, Gonçalves-Sousa N, Rei M, Grosso AR, Penido C, et al.Protective Role of the Inflammatory CCR2/CCL2 Chemokine Pathway through Recruitment of Type 1 Cytotoxic ?d T Lymphocytes to Tumor Beds.J Immunol 2013; 190:6673-80; PMID:23686489; http://dx.doi.org/10.4049/jimmunol.1300434
11. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, et al.Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.J Exp Med 2011; 208:1949-62; PMID:21930770; http://dx.doi.org/10.1084/jem.20101956
12. Rollins BJ, Sunday ME.Suppression of tumor formation in vivo by expression of the JE gene in malignant cells.Mol Cell Biol 1991; 11:3125-31; PMID:2038321
13. Stewart TJ, Lutsiak ME, Abrams SI.Immune consequences of protracted host-tumor interactions in a transgenic mouse model of mammary carcinoma.Cancer Invest 2008; 26:237-49; PMID:18317964; http://dx.doi.org/10.1080/07357900701708419
14. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al.Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.J Immunol 2001; 166:678-89; PMID:11123353
15. Stewart TJ, Abrams SI.Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth.J Immunol 2007; 179:2851-9; PMID:17709499
16. Bronte V, Serafini P, Apolloni E, Zanovello P.Tumor-induced immune dysfunctions caused by myeloid suppressor cells.J Immunother 2001; 24:431-46; PMID:11759067; http://dx.doi.org/10.1097/00002371-200111000-00001
17. Stewart TJ, Liewehr DJ, Steinberg SM, Greeneltch KM, Abrams SI.Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells.J Immunol 2009; 183:117-28; PMID:19542426; http://dx.doi.org/10.4049/jimmunol.0804132
18. Siveen KS, Kuttan G.Role of macrophages in tumour progression.Immunol Lett 2009; 123:97- 102; PMID:19428556; http://dx.doi.org/10.1016/j.imlet.2009.02.011
19. Stewart TJ, Greeneltch KM, Reid JE, Liewehr DJ, Steinberg SM, Liu K, et al.Interferon regulatory factor- 8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells.J Cell Mol Med 2009; 13(9B):3939-50; PMID:20196788; http://dx.doi.org/10.1111/j.1582-4934.2009.00685.x
20. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, et al.Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.Cancer Res 2007; 67:9417-24; PMID:17909051; http://dx.doi.org/10.1158/0008-5472.CAN-07-1286
21. Izhak L, Wildbaum G, Jung S, Stein A, Shaked Y, Karin N.Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis.PLoS One 2012; 7:e28305; PMID:22279523; http://dx.doi.org/10.1371/journal.pone.0028305
22. Chen Q, Zhang XH, Massagué J.Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs.Cancer Cell 2011; 20:538-49; PMID:22014578; http://dx.doi.org/10.1016/j.ccr.2011.08.025
23. Hao NB, Lü MH, Fan YH, Cao YL, Zhang ZR, Yang SM.Macrophages in tumor microenvironments and the progression of tumors.Clin Dev Immunol 2012; 2012:948098; PMID:22778768; http://dx.doi.org/10.1155/2012/948098
24. Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ.Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.Expert Rev Mol Diagn 2011; 11:91- 100; PMID:21171924; http://dx.doi.org/10.1586/erm.10.97
25. De Palma M, Lewis CE.Cancer: Macrophages limit chemotherapy.Nature 2011; 472:303-4; PMID:21512566; http://dx.doi.org/10.1038/472303a
26. Guy CT, Cardiff RD, Muller WJ.Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.Mol Cell Biol 1992; 12:954-61; PMID:1312220
27. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al.Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.Am J Pathol 2003; 163:2113-26; PMID:14578209; http://dx.doi.org/10.1016/S0002-9440(10)63568-7